Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.19.3.a.u2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
9 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Cash flows from operating activities:    
Net income (loss) [1] $ (7,262) $ (3,336)
Reconciliation of net loss to net cash used in operating activities:    
Depreciation and amortization 1,426 3,092
Stock-based compensation 597 889
Loss (gain) on sale of fixed assets (11) 1
Restructuring 234  
Exchange rate loss (gain) (2) 3
Changes in assets and liabilities:    
Accounts receivable 1,934 1,892
Inventories 2,179 (941)
Prepaid expenses and other current assets 3 (353)
Other assets (575) 11
Deferred revenue (79) (1,114) [2]
Accounts payable and accrued expenses 332 494
Net cash provided by (used in) operating activities (1,224) 638
Cash flows from investing activities:    
Maturities of other short-term investments   2,779
Proceeds from sale of fixed assets 11  
Purchase of product licensing rights (1,950) [3] 0
Purchases of property and equipment (113) (273)
Net cash provided by (used in) investing activities (2,052) 2,506
Cash flows from financing activities:    
Purchases of treasury stock (191) (1,038)
Net cash provided by (used in) financing activities (191) (1,038)
Gain (loss) of exchange rate changes on cash 0 (4)
Net increase (decrease) in cash and cash equivalents (3,467) 2,102
Net increase (decrease) in cash and cash equivalents 25,457 24,963
Cash and cash equivalents, end of period $ 21,990 $ 27,065
[1] Net income (loss) and comprehensive income (loss) are the same for the periods reported.
[2] Includes the cumulative effect adjustment of the ASC 606 adoption.
[3] During the quarter ended September 30, 2019, the Company made a $950,000 payment for the purchase of product licensing rights. The remaining $1.0 million that is due is recorded in Accounts Payable as of December 31, 2019. The corresponding asset is recorded in intangible assets.